Health Economics & Evidence Synthesis
Assessing and demonstrating value that drives access, reimbursement and healthcare decision-making
We help pharmaceutical, biotech and medtech organisations generate the evidence and analytics needed to demonstrate value, navigate reimbursement processes and support successful market access. From systematic literature reviews and evidence synthesis through to health economic modelling and value communication, we combine scientific rigour with strategic insight to help clients make stronger decisions and achieve better outcomes.
The challenge
Demonstrating value is becoming increasingly complex
Healthcare decision-makers face growing pressure to allocate limited resources effectively, making evidence requirements more rigorous than ever. Demonstrating clinical benefit alone is rarely enough to secure reimbursement, market access or widespread adoption. Payers, HTA bodies and healthcare systems increasingly require robust evidence on comparative effectiveness, cost-effectiveness and real-world value.
Organisations must navigate complex and evolving evidence expectations while addressing uncertainty and evidence gaps. Without a clear evidence strategy, even highly innovative products can struggle to achieve their full commercial potential.
Our approach
Combining scientific excellence with real-world decision-making expertise
Our Health Economics & Evidence Synthesis team brings together specialists in evidence generation, statistics, health economics, health technology assessment and value communication. We understand not only how evidence is created, but how it is assessed and applied by healthcare decision-makers.
We help clients develop evidence strategies that drive and align with stakeholder requirements, ensuring research investments generate meaningful insights that are clearly communicated to support commercial objectives. By connecting robust analytics with a deep understanding of multi-stakeholder needs, we help organisations build stronger value propositions and more compelling evidence packages.
The evidence landscape
Understanding who evaluates evidence and why it matters
Successful evidence strategies begin with understanding the stakeholders who will assess your product and the evidence requirements that shape their decisions.
Health Technology Assessment bodies
Organisations such as NICE in the UK and other HTA agencies worldwide evaluate clinical and economic evidence to determine value and reimbursement suitability.
Payers and reimbursement authorities
National and regional payers assess affordability, budget impact and comparative effectiveness when making funding decisions.
Healthcare providers and clinical leaders
Clinicians and provider organisations require evidence that innovations improve patient outcomes and support efficient care delivery.
Researchers and guideline developers
Academic experts and guideline bodies influence evidence standards, treatment pathways and future adoption opportunities.
what we do
Health Economics & Evidence Synthesis
Our HEOR & Evidence Synthesis capability combines with our strategic and communications expertise to help organisations generate, analyse and communicate the evidence needed to support market access.
Systematic review and evidence synthesis
Our systematic reviews are conducted in accordance with internationally recognised guidelines and meet the standards of HTA bodies. We have specialist expertise in evidence synthesis and provide resourceful, innovative solutions based on data availability and jurisdiction requirements.
Statistical analysis
Our statistical team are experts in the full range of analyses required to inform economic evaluations, as well as in evidence synthesis and design and analysis of clinical trials, observational studies and real-world evidence datasets. We can also advise on the strategic implications of different analytical approaches for HTA.
Economic modelling
We are experts in modelling for every stage of your product’s life cycle, including early decision-making models, pricing models, cost-effectiveness and budget impact models, and interactive payer-facing modelling tools.
Real-world evidence
We can help identify the most robust real-world data for your needs and design studies to inform clinical strategy, enhance market access and support regulatory submissions.
Health technology assessment
Our first-class strategic, technical and communications expertise makes us outstanding partners for your HTA submissions.
Value communication
We combine our deep understanding of payer evidence requirements with our communications expertise to develop materials that demonstrate value to payers, clinicians and decision-makers.
how we work
From evidence generation to market impact
We combine technical expertise with practical strategic support, helping organisations move from identifying evidence needs through to generating insights and communicating value effectively.
Understand the landscape
From global early value assessments to country-level reimbursement submissions, our process begins with a full assessment of the product within the wider clinical and payer landscape to identify key drivers of value for each stakeholder archetype.
Develop the strategy
We design evidence generation and communication approaches that are tailored to address payer and clinician priorities, combining our technical expertise with our wealth of multi-stakeholder experience.
Generate robust evidence
From health economic models and data analysis to value dossiers and literature reviews, our team works collaboratively to create a consistent and compelling evidence package.
Provide sustained support
We understand both global needs and local requirements, meaning we can provide ongoing support to adapt, tailor and diversify each product’s value evidence package to new markets.
The outcome
Evidence that supports confident decision-making
Our clients value the combination of scientific rigour, analytical expertise and practical market access understanding that we bring to every engagement. We help organisations generate evidence that stands up to scrutiny, supports reimbursement and demonstrates meaningful value to healthcare decision-makers.
Founded to help the best health innovations reach patients faster
Global pharma, biotech, medtech and healthcare system clients served
Of clients rank Newmarket Strategy as their top consultancy
specialist capability
Visible Analytics — evidence excellence
Through our acquisition of Visible Analytics, Newmarket Strategy brings world-class health economics and evidence capability in-house. Visible Analytics is a specialist health economics and HTA consultancy with an outstanding track record in economic modelling, statistical analysis, HTA submissions and value communication across global markets.
Their team includes Professor Neil Hawkins — Vice Chair of the NICE Diagnostics Advisory Committee and Professor of HTA at the University of Glasgow — alongside Professor Keith Abrams, Professor of Statistics at the University of Warwick and NICE Diagnostics Advisory Committee member, Noémi Muszbek, expert health economist and member of the NICE Interventional Procedures Advisory Committee, Professor David Scott, Professor at the Southampton Health Technology Assessments Centre and lead on evaluation of ITCs for the NICE Technology Assessment Report programme, and Edit Remák, with 20 years developing economic models for HTA submissions across multiple regions.
Visible Analytics have delivered submissions for 18 HTA agencies globally, developed and adapted economic models across 24 countries, and built a reputation for scientific rigour, strategic focus and transparent communication of results.
Our team
Practical advice from people who understand the market
Newmarket Strategy brings together market access specialists, healthcare policy experts, clinicians, analysts and commercial strategists.
Related case studies
Continue reading
What we do
Pillars of our expertise
Newmarket Strategy has industry-leading expertise supporting market access strategy through policy, reimbursement and evidence synthesis.
Value & Access
Empowering organisations to set commercial strategy, demonstrate value and secure reimbursement.
Global Health Policy & Government Affairs
Helping organisations navigate complex political landscapes, influence decision makers, and shape health policy.
Health Economics & Evidence Synthesis
Harnessing robust data and economic modelling to build a compelling evidence base and drive market uptake.
